Nerve Cuff approved for use in US DoD and VA hospitals
Released
Released
Announcement PDF
+61 (03) 9482 3940
157 Heidelberg Rd,
Northcote, VIC 3070
www.renerve.com.au
ASX Announcement
13 November 2025
NervAlign® approved for use in US Department of Defense (DoD) & Veterans
Affairs (VA) healthcare systems
• NervAlign® Nerve Cuff approved for use in DoD and VA hospitals
• Initial order and reorder received from the DoD and VA network
• Further validation of the quality of NervAlign® in peripheral nerve repair
ReNerve Limited (ASX, "ReNerve" or "the Company"), a leading Australian medical device innovator focused on
solutions for peripheral nerve injury (PNI), is pleased to announce that its NervAlign® Nerve Cuff has been
approved for use across the US Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems,
representing a significant endorsement of ReNerve’s NervAlign® nerve cuff technology.
The approval allows the NervAlign® Nerve Cuff to be used across the DoD's 51 military hospitals and 424 clinics, as
well as VA's 170 medical centres and over 1,193 outpatient facilities, providing ready access to this innovative
technology to those of the approximately 9.5 million patients across both healthcare systems who may benefit
from its use.
Under this approval, ReNerve has received both an initial purchase order and a subsequent repeat order from
federal medical facilities, demonstrating early confidence in the NervAlign® system. These orders will enable
immediate deployment of the technology to select facilities within both the DoD and VA networks, with a broader
rollout planned for the coming months.
"This approval represents major progress in our mission to provide superior nerve repair solutions to those who
need them most," said Dr Julian Chick, CEO of ReNerve. "Military service members and veterans often face complex
peripheral nerve injuries, and we are honoured and proud that the NervAlign® Nerve Cuff will now be available to
support their recovery and rehabilitation."
The NervAlign® Nerve Cuff represents a significant advancement in peripheral nerve repair technology, offering
clinicians a precise and effective solution for supporting nerve regeneration and recovery following traumatic
injuries, surgical procedures, and other conditions affecting peripheral nerves.
About the Federal Healthcare Networks
The Military Health System operates through the Defence Health Agency, managing healthcare delivery across 51
hospitals and 424 clinics serving military personnel, their families, and retirees. The Veterans Health Administration
operates the largest integrated healthcare system in the United States, with 170 medical centres and 1,193
outpatient sites of care, providing comprehensive medical services to veterans nationwide.
2 | P a g e
Visit renerve.com.au for more details and updates on ReNerve products and clinical news.
- ENDS -
This announcement has been approved for release by the Company’s Board of Directors.
For further information and enquiries, please contact:
Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au
Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au
About ReNerve Limited (ASX:RNV)
ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical
technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device
company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral
nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients
worldwide.
Proven Clinical Success
ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference
in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable
results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores
dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant
improvement that's changing lives.
Comprehensive Product Portfolio
ReNerve is advancing a complete suite of nerve repair solutions:
• NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of
surgery.
• Deep Dermal tissue product -- A unique deep dermal product used in the repair of reconstructive and
cosmetic surgical cases.
• Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing of wounds.
• NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO
technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
• NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for
treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to
undergo additional sural nerve harvesting.
3 | P a g e
• NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve
repairs.
Market Leadership and Growth
With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue
growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution
for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at
US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1
Vision and Values
We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for
nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's
natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve
surgery.
1
Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)
Share your feedback
Discover